Study of Apatinib in Metastatic Esophageal Cancer

Inclusion Criteria: 1. Age: 18 to75 years old; 2. Pathologically diagnosed with metastatic esophageal squamous cell cancer with measurable metastases outside the stomach (measuring ≥ 10mm on spiral CT scan, satisfying the criteria in RECIST 1.1); 3. Failed in first-line chemotherapy or radiotherapy treatment; 4. ECOG PS of 0-1; 5. An expected survival of ≥ 3 months; 6. No treated by molecularly targeted therapy. If have received chemotherapy, radiotherapy or surgery, must ≥4 weeks, and adverse reactions or wound has been completely restored; 7. Major organ function has to meet the following criteria: ANC ≥ 1.5 × 109 / L; HB ≥ 90g / L; PLT ≥ 100 × 109 / L; ALB≥30g / L; TBIL≤1.5 times the upper limit of normal (ULN); ALT and AST\<2 × ULN; Plasma Cr\<1.5 × ULN 8. Patient has to voluntarily join the study and sign the Informed Consent Form for the study; 9. Researchers believe that patients can benefit; Exclusion Criteria: 1. Pts with other malignant tumor at the same time or in the past. 2. Pregnant or lactating women; 3. Subjects with poor-controlled arterial hypertension (systolic blood pressure\>150 mmHg and diastolic blood pressure\>100 mm Hg) despite standard medical management; Coronary heart disease greater than ClassII; Echocardiography: LVEF (LVEF)\<50%; 4. Factors that could have an effect on oral medication (such as inability to swallow, chronic diarrhea and intestinal obstruction); 5. Subjects with high gastrointestinal bleeding risk, including the following conditions: local active ulcer lesions with positive fecal occult blood test (++); history of black stool, or vomiting blood in the past 6 months; 6. Associated with CNS (central nervous system) metastases; 7. Abnormal Coagulation, with tendency of bleed; 8. With psychotropic drug abuse history and can't get rid of or mental disorder patients; 9. Anastomotic recurrence; 10. Participated in other clinical trials within 4 weeks; 11. Any other condition that might place the patient at undue risk or preclude a patient from completing the study; 12. Other conditions regimented at investigators' discretion.